WARREN, N.J. - PTC Therapeutics, Inc. (NASDAQ: NASDAQ:PTCT) has disclosed that the U.S. Food and Drug Administration (FDA) has slated July 29, 2025, as the target date to complete its review of the New Drug Application (NDA) for sepiapterin. This drug is intended for the treatment of phenylketonuria (PKU) in both pediatric and adult patients, covering all age groups and disease subtypes.
The company also announced the recent publication of the Phase 3 APHENITY trial results in The Lancet, a leading medical journal. The trial findings suggest that sepiapterin could address a significant unmet medical need in PKU treatment. Matthew B. Klein, M.D., CEO of PTC (NASDAQ:PTC) Therapeutics, commented on the publication, highlighting the data's promising nature.
Sepiapterin, which is an oral synthetic formulation, functions by enhancing the activity of the phenylalanine hydroxylase (PAH) enzyme through two mechanisms. It serves as a precursor that converts to tetrahydrobiopterin (BH4), a crucial cofactor for PAH, and also acts as a pharmacological chaperone to correct enzyme misfolding. The drug has demonstrated potential in reducing blood phenylalanine levels, which is key in treating PKU.
PKU is a rare inherited disorder that affects the brain by impairing the breakdown of phenylalanine, an amino acid present in proteins and most foods. Without treatment or with inadequate management, phenylalanine can accumulate to harmful levels, leading to severe disabilities.
The NDA submission for sepiapterin includes data from the APHENITY trial as well as from an ongoing open-label extension study. The latest results indicate that around 60% of participants could achieve protein intake beyond the recommended daily allowance while maintaining control of phenylalanine levels.
PTC Therapeutics is a biopharmaceutical company that focuses on rare disorders, striving to provide access to treatments for patients with limited options. The company's strategy relies on its scientific and clinical expertise and global commercial infrastructure to deliver therapies to patients and maximize stakeholder value.
The information in this article is based on a press release statement from PTC Therapeutics.
In other recent news, PTC Therapeutics has seen significant progress in its vatiquinone treatment program for Friedreich ataxia, showing a substantial slowing of disease progression. The company has reported a Q2 2024 revenue of $187 million, primarily driven by its Duchenne muscular dystrophy franchise, and revised its full-year revenue guidance to a range of $700 million to $750 million. Analyst firms Raymond James, Baird, Goldman Sachs, and TD Cowen have provided their assessments of the company, with Raymond James issuing a Market Perform rating, Baird reaffirming an Outperform rating, Goldman Sachs maintaining a Sell rating, and TD Cowen holding steady with a Hold rating. The FDA has accepted PTC Therapeutics' New Drug Application for sepiapterin, a potential treatment for phenylketonuria (PKU), and granted Fast Track Designation to the company's drug candidate PTC518, developed for Huntington's disease treatment. Lastly, PTC Therapeutics completed the sale of their gene therapy manufacturing business, receiving an upfront payment of $27.5 million. These are the recent developments surrounding PTC Therapeutics.
InvestingPro Insights
PTC Therapeutics' recent FDA update on sepiapterin aligns with several key financial indicators from InvestingPro. The company's market cap stands at $3.02 billion, reflecting investor confidence in its pipeline and potential for growth in the rare disease space.
InvestingPro data shows that PTC Therapeutics has experienced significant momentum, with a strong 91.27% price return over the past year. This surge likely reflects market optimism about the company's drug development progress, including the sepiapterin NDA.
Despite the positive news on sepiapterin, InvestingPro Tips caution that analysts anticipate a sales decline in the current year, and the company is not expected to be profitable this year. This underscores the importance of the FDA's decision on sepiapterin for PTC's future revenue streams.
Interestingly, PTC's liquid assets exceed short-term obligations, suggesting financial stability as it navigates the regulatory process. However, the company is trading at a high EBITDA valuation multiple, indicating that investors are pricing in future growth potential, possibly tied to the success of drugs like sepiapterin.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for PTC Therapeutics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.